Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

N/ANot Yet RecruitingNCT07344987

Peking Union Medical College100 enrolled

Overview

Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

100

Conditions

ILD

Interventions

Air Purifier (with Filter) Arm

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with interstitial lung disease (ILD). * Stable disease status, defined as no hospitalization due to acute exacerbation within the past month. Exclusion Criteria: * Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders. * A history of respiratory tract infection within the past two weeks.

Outcomes

Primary Outcomes

Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)

St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

Quality of Life Indicators (e.g., CAT Score)

COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

Blood Sample Indicators (e.g., Concentration of Interleukin-8)

Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8

Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)